

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

				Complete if Known	
				Application Number	National Entry of PCT/EP03/06591
				Filing Date	Herewith 10/517338
				First Named Inventor	Sven Ole WARNAAR et al
				Group Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	2923-672

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CJ		Beck Joachim et al., "A Phase I/II trial with monoclonal antibody WX-G250 in combination with low dose interleukin-2 in metastatic renal cell carcinoma", PROCEEDINGS OF THE AMERICA ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 43, March 2002, pg. 910.	
		Bleumer I et al., "A phase II trial with monoclonal antibody WX-G250 in advanced renal cell carcinoma", EUROPEAN UROLOGY SUPPLEMENTS, vol. 1, no. 1, January 2002, pg. 112.	
		Liu Zhanqi et al., "Anti-renal cell carcinoma chimeric antibody G250: Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 51, no. 3, May 2002, pgs. 171-177.	
		Van Dijk J. et al., "Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts", INTERNATIONAL JOURNAL OF CANCER, vol. 56, no. 2, 1994, pgs. 262-268.	
		Varga Z et al., "A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients", FOLIA BIOLOGICA, vol. 49, no. 2, 2003, pgs. 74-77.	
✓		Bleumer Ivar et al., "A phase I/II trial with chimeric monoclonal antibody WX-G250 in combination with low-dose interleukin-2 for patients with metastatic renal cell carcinoma", JOURNAL OF UROLOGY, vol. 169, no. 4 Supplement, April 2003, pg. 261.	
Examiner Signature	<i>Catherine Jayne</i>		Date Considered 9/20/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.